Genetic control of the phenobarbital-induced shortening of plasma antipyrine half-lives in man

Veseli, Elliot S.; Page, John G.

doi:10.1172/jci106186

Cited by 251 publications

(104 citation statements)

References 18 publications

(18 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Furthermore the increased coefficient of correlation between antipyrine clearance and liver volume implied that variance in drug metabolising capacity per unit mass of liver decreased. This would be consistent with the decreased variance in antipyrine half-life known to occur after enzyme induction with phenobarbitone (Vesell and Page, 1969).…”

Section: Discussionsupporting

confidence: 78%

The relationship between liver volume, antipyrine clearance and indocyanine green clearance before and after phenobarbitone administration in man.

Roberts¹,

Jackson²,

Halliwell³

et al. 1976

Brit J Clinical Pharma

View full text Add to dashboard Cite

General Hospital, Bristol I Liver volume and the clearances of antipyrine and indocyanine green have been measured before and after administration of phenobarbitone (180 mg/day) for 3 weeks to ten healthy subjects. 2 The measurement of liver volume by an ultrasound scanning technique yielded reproducible results which were consistent with predictions of liver size by allometric methods. 3 Before phenobarbitone, antipyrine clearance correlated with liver volume, but there was no correlation between indocyanine green clearance and liver volume. 4 Phenobarbitone administration increased the clearance of antipyrine significantly by 90 ± 14% but there was no significant change in indocyanine green clearance or liver volume. 5 After phenobarbitone the correlation between antipyrine clearance and liver volume persisted. There was no correlation between indocyanine green clearance and liver volume. 6 These results suggest that in non-medicated subjects some of the difference in antipyrine clearance is due to difference in functional hepatic parenchymal mass and that phenobarbitone increases the drug metabolising capacity per unit of hepatic mass but not total liver size.

show abstract

Section: Discussionsupporting

confidence: 78%

The relationship between liver volume, antipyrine clearance and indocyanine green clearance before and after phenobarbitone administration in man.

Roberts¹,

Jackson²,

Halliwell³

et al. 1976

Brit J Clinical Pharma

View full text Add to dashboard Cite

show abstract

“…the same patient group, eliminating confounding factors like interindividual response to enzyme inducing agents (Vesell & Page 1969) and variation in life style like dietary habits (Longcope et al 1987, Michnovicz & Bradlow 1990. We hypothesised that ERT given orally would cause a more marked increase in plasma Oe 1 S and the ratio of Oe 1 S to Oe 1 and Oe 1 S to Oe 2 compared with parenteral treatment.…”

Section: Sex Hormone Binding Globulin (Nmol/l)mentioning

confidence: 99%

Plasma oestrogen fractions in postmenopausal women receiving hormone replacement therapy: influence of route of administration and cigarette smoking

Geisler¹,

Omsjø²,

Helle³

et al. 1999

Journal of Endocrinology

View full text Add to dashboard Cite

The aim of this study was to determine the impact of the administration route and cigarette smoking on plasma oestrogen levels during oral and parenteral oestrogen replacement therapy (ERT). Fourteen healthy postmenopausal women (six smokers and eight non-smokers) were recruited for a prospective, randomised, crossover study at a private outpatient medical centre in Oslo, Norway. All patients were randomised to receive cyclic therapy with oestradiol and norethisterone orally or by the transdermal route each for a 6-month period. Plasma levels of oestrone (Oe 1 ), oestradiol (Oe 2 ) and oestrone sulphate (Oe 1 S) were determined using highly sensitive RIA methods before and during hormone replacement therapy given by the oral and transdermal route. Comparing smokers and nonsmokers, plasma levels of Oe 1 , Oe 2 and Oe 1 S were all found to be 40-70% lower in smokers compared with non-smokers when ERT was given orally (Oe 1 S, P<0·05; Oe 1 and Oe 2 , P<0·01 for both). Oe 2 given orally caused a higher Oe 1 S/Oe 2 ratio but also a higher Oe 1 /Oe 2 ratio compared with parenteral therapy in smokers (40·2 versus 7 . 0, P<0·01; and 3·2 versus 0·8, P<0·05 respectively). No significant differences in these parameters in the different test-situations were seen in non-smokers. Except for a lower level of Oe 1 S in smokers (non-significant), no difference in plasma oestrogen levels between smokers and non-smokers was observed during parenteral therapy. In conclusion, cigarette smoking has been shown to have major impact on plasma oestrogen levels during oral but not during parenteral Oe 2 replacement.

show abstract

“…Indirect methods based on the rate of plasma clearance of antipyrine or phenylbutazone are not suitable because of species and genetic variability of drug detoxication (18). Furthermore, an exogenous bilirubin load in neonates (3) is not appropriate because of further bilirubin increase at this age.…”

Section: Speculationmentioning

confidence: 99%

Glucaric Acid Excretion as Index of Hepatic Glucuronidation in Neonates after Phenobarbital Treatment

1975

View full text Add to dashboard Cite

Genetic control of the phenobarbital-induced shortening of plasma antipyrine half-lives in man

Cited by 251 publications

References 18 publications

The relationship between liver volume, antipyrine clearance and indocyanine green clearance before and after phenobarbitone administration in man.

The relationship between liver volume, antipyrine clearance and indocyanine green clearance before and after phenobarbitone administration in man.

Plasma oestrogen fractions in postmenopausal women receiving hormone replacement therapy: influence of route of administration and cigarette smoking

Glucaric Acid Excretion as Index of Hepatic Glucuronidation in Neonates after Phenobarbital Treatment

Contact Info

Product

Resources

About